keyword
MENU ▼
Read by QxMD icon Read
search

Mesoglycan

keyword
https://www.readbyqxmd.com/read/26520894/mesoglycan-improves-vascular-reactivity-and-insulin-sensitivity-in-patients-with-metabolic-syndrome
#1
RANDOMIZED CONTROLLED TRIAL
Antonio Valvano, Giorgio Bosso, Valentina Apuzzi, Filippo Riccone, Luigi Saccà, Ugo Oliviero
OBJECTIVES: The aim of this study was to evaluate the acute and chronic effects of mesoglycan on the endothelial function and arterial elastic properties in patients with metabolic syndrome (MetS). BACKGROUND: MetS is defined by a clustering of vascular risk factors that demand both pharmacologic and non-pharmacologic interventions, including body weight reductions and physical activity. The correction of endothelial dysfunction and arterial wall distensibility associated with MetS have lately received increasing interest...
December 2015: Atherosclerosis
https://www.readbyqxmd.com/read/26036247/pharmacological-adjuncts-for-chronic-venous-ulcer-healing-a-systematic-review
#2
Lavanya Varatharajan, Ankur Thapar, Tristan Lane, Alex B Munster, Alun Huw Davies
BACKGROUND: The aim of this study was to systematically review the current evidence and determine whether there is a clinical benefit for using pharmacological agents as adjunctive treatment for chronic venous ulcers. METHOD: A systematic review of the MEDLINE and EMBASE (from 1 January 1947 through 15 August 2013) and Cochrane databases (from inception through 15 August 2013) was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines...
June 2016: Phlebology
https://www.readbyqxmd.com/read/25972138/flow-mediated-dilation-benefits-of-mesoglycan-in-peripheral-artery-disease
#3
MULTICENTER STUDY
B Gossetti, P L Antignani, J Jabbour, O Martinelli
AIM: Mesoglycan, composed of natural glycosaminoglycans, is used for treatment in arterial and venous disease for its benefits on endothelial glicocalix. Little is known about mesoglycan impact on endothelial blood flow regulation. We sought to evaluate the effects of mesoglycan intermittently added to back-ground treatments on impairment of endothelial function in peripheral arterial disease (PAD) patients. METHODS: We studied the effects of a 2+2 months oral treatment with 50 mg b...
August 2015: International Angiology: a Journal of the International Union of Angiology
https://www.readbyqxmd.com/read/25711836/restoring-microvascular-efficiency-with-mesoglycan-in-women-affected-by-moderate-chronic-venous-disease
#4
L Maresca, C Foggia, G Leonardo
AIM: Chronic venous disorders (CVDs) subtend a spectrum of vascular abnormalities, including microcirculation and skin damages (as ulcers) in the lower limb. Mesoglycan has been established as an effective agent to improve microcirculation associated with CVDs. The aim of this study was to determine the beneficial function of mesoglycan on cutaneous blood flow measured by laser Doppler fluometry (LDF) before and after iontophoresis analysis using methacholine chloride (MCh) injection in a group of female patients in different stages of CVDs, according to the CEAP classification...
April 2015: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/24806325/endovascular-treatment-of-chronic-cerebro-spinal-venous-insufficiency-in-patients-with-multiple-sclerosis-modifies-circulating-markers-of-endothelial-dysfunction-and-coagulation-activation-a-prospective-study
#5
Mariasanta Napolitano, Aldo Bruno, Diego Mastrangelo, Marcella De Vizia, Benedetto Bernardo, Buonagura Rosa, Domenico De Lucia
We performed a monocentric observational prospective study to evaluate coagulation activation and endothelial dysfunction parameters in patients with multiple sclerosis undergoing endovascular treatment for cerebro-spinal-venous insufficiency. Between February 2011 and July 2012, 144 endovascular procedures in 110 patients with multiple sclerosis and chronical cerebro-spinal venous insufficiency were performed and they were prospectively analyzed. Each patient was included in the study according to previously published criteria, assessed by the investigators before enrollment...
October 2014: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/24566500/quality-of-live-as-measured-by-the-civq-20-questionnaire-following-oral-mesoglycan-treatment-of-patients-with-chronic-venous-disease
#6
MULTICENTER STUDY
C Allegra, P L Antignani
AIM: Several studies have demonstrated the effective antithrombotic action of mesoglycan to treat chronic venous disease (CVD). The study aimed to assess clinical and quality of life (QoL) (CIVIQ 20 questionnaire) improvements in mesoglycan-treated patients with clinical, etiological, anatomical and pathophysiological (CEAP) stages 2 and 3. METHODS: The open, multicentre, uncontrolled, observational, prospective study involved treating patients with 50 mg x 2/day mesoglycan for 2 months and measuring improvement to lower-limb edema and QoL in the Global, Physical, Pain, Psychological, and Social Dimensions of the Chronic Venous Disease Quality-of-Life Questionnaire (CIVIQ 20) at the first, baseline visit (V1), at the end of treatment (V2) and 2 (V3) and 4 months after treatment completion (V4)...
October 2014: International Angiology: a Journal of the International Union of Angiology
https://www.readbyqxmd.com/read/23681135/mesoglycan-treatment-in-raynaud-phenomenon-a-case-series
#7
A Di Biase
AIM AND METHODS: Raynaud's phenomenon (RP) is a common clinical disorder without cure or gold standard therapy. Mesoglycan is an well-balanced extract of glycosaminoglycans active on endothelial layers at microcirculatory level. Herein we investigated for the first time the efficacy and tolerability of mesoglycan on vasospastic attacks and videocapillaroscopy patterns in 25 consecutive patients with primary or secondary RP. RESULTS AND CONCLUSION: During 12 months of add-on therapy, mesoglycan obtained a remarkable and significant reduction in the frequency of Raynaud attacks and an improvement of the capillaroscopy abnormalities in most patients, without important adverse effects, revealing a good convenience in the management if this condition...
June 2013: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/23492605/treating-telangiectasias-my-method
#8
F Ferrara, G Ferrara
AIM: The authors propose a new classification of telangiectasias: conditions involving demonstrated reflux are classified as type A telangiectasias; clustered, spider telangiectasias not related to reflux and with vein diameters of >0.2 mm are classified as type B, while isolated telangiectatic veins of ≤0.2 mm diameter are classed as type C. This histological and pathophysiological approach is the basis for the Authors' Multi-Therapy Treatment Protocol (MTT). METHODS: The treatment regimen provides for initial treatment of type A telangiectasias with just conventional reflux sclerotherapy, followed three weeks later by treatment of type B telangiectasias with 0...
April 2013: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/22362228/a-pilot-clinical-study-on-the-effectiveness-of-mesoglycan-against-diabetic-retinopathy
#9
RANDOMIZED CONTROLLED TRIAL
E Pacella, F Pacella, P Turchetti, F Mazzeo, R Anzidei, A Malvasi, K G Malarska, C Brillante, C Balocco Gabrieli
PURPOSE: A double-blind placebo-controlled study on 68 patients suffering by Diabetic Retinopathy was aimed in order to evaluate the effectiveness of Mesoglycan in this pathology. This drug is particularly interested in treatment of disorders of microcirculation. MATERIALS AND METHODS: The two treatments were randomly assigned to each patient, using a 100 mg/day dosage of Mesoglycan, and both treatments were prescribed for 6 months. The efficacy of both treatments was based on clinical and instrumental check...
2012: La Clinica Terapeutica
https://www.readbyqxmd.com/read/22189344/venous-leg-ulcers
#10
REVIEW
E Andrea Nelson
INTRODUCTION: Leg ulcers usually occur secondary to venous reflux or obstruction, but 20% of people with leg ulcers have arterial disease, with or without venous disorders. Between 1.5 and 3.0/1000 people have active leg ulcers. Prevalence increases with age to about 20/1000 in people aged over 80 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of standard treatments, adjuvant treatments, and organisational interventions for venous leg ulcers? What are the effects of advice about self-help interventions in people receiving usual care for venous leg ulcers? What are the effects of interventions to prevent recurrence of venous leg ulcers? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2011 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review)...
December 21, 2011: Clinical Evidence
https://www.readbyqxmd.com/read/21811066/clopidogrel-effectively-suppresses-endothelial-microparticle-generation-induced-by-indoxyl-sulfate-via-inhibition-of-the-p38-mitogen-activated-protein-kinase-pathway
#11
Jung-Hwa Ryu, Seung-Jung Kim
BACKGROUND/AIMS: Endothelial microparticles (EMPs) are closely associated with vascular dysfunction. We investigated the effects of several drugs on EMP generation in human umbilical vein endothelial cells (HUVECs), and the involvement of the mitogen-activated protein kinase (MAPK) in EMP generation. METHODS: CD31+CD42-EMP counts were measured by flow cytometry in supernatants of HUVECs incubated with indoxyl sulfate. The EMP responses to losartan, lovastatin, clopidogrel, and mesoglycan were examined...
2011: Blood Purification
https://www.readbyqxmd.com/read/21152191/mesoglycan-clinical-evidences-for-use-in-vascular-diseases
#12
Antonella Tufano, Claudia Arturo, Ernesto Cimino, Matteo Nicola Dario Di Minno, Mirko Di Capua, Anna Maria Cerbone, Giovanni Di Minno
Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be involved in several biologic functions. Mesoglycan, a natural GAG preparation, is a polysaccharide complex rich in sulphur radicals with strong negative electric charge. It is extracted from porcine intestinal mucosa and is composed of heparan sulfate, dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate. Data on antithrombotic and profibrinolytic activities of the drug show that mesoglycan, although not indicated in the treatment of acute arterial or venous thrombosis because of the low antithrombotic effect, may be useful in the management of vascular diseases, when combined with antithrombotics in the case of disease of cerebral vasculature, and with antithrombotics and vasodilator drugs in the case of chronic peripheral arterial disease...
2010: International Journal of Vascular Medicine
https://www.readbyqxmd.com/read/19577328/alopecia-secondary-to-mesotherapy
#13
Bruna Duque-Estrada, Colombina Vincenzi, Cosimo Misciali, Antonella Tosti
Mesotherapy has recently become an advertised method for the treatment of different types of alopecia despite the lack of any data regarding its efficacy and possible side effects. The substances injected into the scalp include "cocktails" of natural plant extracts, homoeopathic agents, vitamins, vasodilators, and drugs that may stimulate hair growth, such as finasteride and minoxidil. We report two cases of patchy alopecia that developed after mesotherapy for the treatment of androgenetic alopecia. In the first patient, alopecia developed after injections of the heparinoid vasodilator mesoglycan; the 3-month follow-up examination revealed a small residual area of cicatricial alopecia...
October 2009: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/19445798/venous-leg-ulcers
#14
REVIEW
E Andrea Nelson, June Jones
INTRODUCTION: Leg ulcers usually occur secondary to venous reflux or obstruction, but 20% of people with leg ulcers have arterial disease, with or without venous disorders. Between 1.5 and 3.0/1000 people have active leg ulcers. Prevalence increases with age to about 20/1000 in people aged over 80 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of standard treatments, adjuvant treatments, and organisational interventions for venous leg ulcers? What are the effects of interventions to prevent recurrence of venous leg ulcers? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2007 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review)...
September 15, 2008: Clinical Evidence
https://www.readbyqxmd.com/read/19270639/pharmacological-treatment-of-mechanical-edema-a-randomized-controlled-trial-about-the-effects-of-mesoglycan
#15
RANDOMIZED CONTROLLED TRIAL
T Viliani, M Scarselli, A Pieri, M Gatti, M Santini, P Pasquetti
AIM: Mechanical edema (MO) is frequently found in a lot of the lower extremities' orthopedic diseases. In absence of deep vein thrombosis, MO is caused by the change in the dynamics of calf muscle pump with venous hypertension and by the change in capillary permeability which offsets the extra-vascular fluid balance resulting in edema formation. The correct treatment includes specific training for musculo-skeletal and gait recovery, together with medical treatment focused on venous endothelium...
March 2009: European Journal of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/18091643/effectiveness-of-mesoglycan-in-patients-with-previous-deep-venous-thrombosis-and-chronic-venous-insufficiency
#16
COMPARATIVE STUDY
G M Andreozzi
AIM: Retrospective analysis of mesoglycan therapeutic activity in venous disorders. The clinical data have been selected from the outpatient database of the Chair of Angiology of the University of Catania (from 1988 to 1997) through a cross survey between the prescription commercial name of mesoglycan and the key words varicose veins, deep venous thrombosis (DVT), chronic venous insufficiency (CVI), post-thrombotic syndrome (PTS), venous thrombosis, venous ulcer. METHODS: Patients have been selected on the basis of definite data relative to principal diagnosis, clinical history, clinical and instrumental objective phlebological picture, posology and duration of treatment, follow-up visits in the first three years following the first observation...
December 2007: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/13679662/dermatan-sulphate-as-an-antithrombotic-drug
#17
REVIEW
Giuseppe G Nenci
Dermatan sulphate (DS) is a glycosaminoglycan which selectively catalyzes the inactivation of thrombin by Heparin Cofactor II without interacting with Antithrombin III. DS does not interact with other coagulation factors and, unlike heparin, is able to inactivate thrombin bound to fibrin or to the surface of an injured vessel. Efficacy and safety of DS have been validated in studies on thromboprophylaxis and on the anticoagulation for hemodialysis. Studies on thromboprophylaxis have been performed in "medical" patients as well as in general, orthopedic and oncological surgery...
September 2002: Pathophysiology of Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/11816704/treatment-of-intermittent-claudication-with-mesoglycan-a-placebo-controlled-double-blind-study
#18
RANDOMIZED CONTROLLED TRIAL
G G Nenci, P Gresele, G Ferrari, L Santoro, F Gianese et al.
OBJECTIVE: To assess the effect of treatment with mesoglycan, a sulphated polysaccharide compound, on the walking capacity of patients with stage II peripheral arterial disease. METHODS: Non-diabetic outpatients with intermittent claudication, duplex ultrasound evidence of peripheral atherosclerosis, ankle/arm index <0.80, systolic ankle pressure >50 mmHg, and absolute walking distance (AWD) between 100 and 300 m (standardised treadmill test) were eligible...
November 2001: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/11563899/a-placebo-controlled-double-blind-study-of-mesoglycan-in-the-treatment-of-chronic-venous-ulcers
#19
RANDOMIZED CONTROLLED TRIAL
E Arosio, G Ferrari, L Santoro, F Gianese, S Coccheri
OBJECTIVES: to assess the effect of treatment with mesoglycan, a sulphated polysaccharide compound, on the healing of venous ulcers. Design randomised, placebo-controlled, double-blind, multicentre trial. METHODS: non-diabetic outpatients with chronic venous insufficiency confirmed by duplex ultrasound, normal ankle/arm pressure index and presence of a leg ulcer were eligible. Patients were randomised to mesoglycan, 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally, or matching placebo, as an adjunct to compression therapy and topical wound care...
October 2001: European Journal of Vascular and Endovascular Surgery
https://www.readbyqxmd.com/read/10630070/-effectiveness-of-mesoglycan-topical-treatment-of-leg-ulcers-in-subjects-with-chronic-venous-insufficiency
#20
G La Marca, G Pumilia, A Martino
BACKGROUND: Aim of the present comparative clinical study was to demonstrate the efficacy of the topical application of mesoglycan, a profibrinolytic agent, for healing of leg ulcers in patients with chronic venous insufficiency. METHODS: Forty patients, observed in our outpatients department, with venous leg ulcers have been randomized in two groups of twenty subjects, each treated with topical application of mesoglycan (1 or 2 vials/day) or vegetal stimulins and followed for two months, with controls after 15, 30 and 60 days...
September 1999: Minerva Cardioangiologica
keyword
keyword
85353
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"